Sunbelt Securities Inc. Acquires 7,015 Shares of Pfizer Inc. (NYSE:PFE)

Posted by Defense World Staff on Sep 13th, 2023

Sunbelt Securities Inc. raised its holdings in Pfizer Inc. (NYSE:PFE – Free Report) by 11.0% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 70,815 shares of the biopharmaceutical company’s stock after acquiring an additional 7,015 shares during the quarter. Sunbelt Securities Inc.’s holdings in Pfizer were worth $2,860,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of PFE. BlackRock Inc. lifted its holdings in shares of Pfizer by 0.6% in the 1st quarter. BlackRock Inc. now owns 445,384,893 shares of the biopharmaceutical company’s stock worth $18,171,704,000 after buying an additional 2,516,132 shares during the period. Wellington Management Group LLP lifted its stake in Pfizer by 9.8% in the first quarter. Wellington Management Group LLP now owns 218,931,933 shares of the biopharmaceutical company’s stock worth $8,932,423,000 after acquiring an additional 19,602,359 shares during the period. Moneta Group Investment Advisors LLC lifted its stake in Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after acquiring an additional 160,963,976 shares during the period. Geode Capital Management LLC increased its position in Pfizer by 0.5% during the 1st quarter. Geode Capital Management LLC now owns 109,852,779 shares of the biopharmaceutical company’s stock valued at $4,472,433,000 after purchasing an additional 577,201 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Pfizer by 14.4% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 83,901,181 shares of the biopharmaceutical company’s stock valued at $3,408,836,000 after purchasing an additional 10,560,702 shares in the last quarter. Hedge funds and other institutional investors own 68.05% of the company’s stock.

Pfizer Price Performance

NYSE PFE opened at $34.15 on Wednesday. The company has a market cap of $192.81 billion, a price-to-earnings ratio of 9.08, a PEG ratio of 1.14 and a beta of 0.59. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.12 and a quick ratio of 1.82. The stock’s fifty day moving average price is $35.90 and its 200 day moving average price is $38.09. Pfizer Inc. has a 1 year low of $33.54 and a 1 year high of $54.93.

Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.10. Pfizer had a return on equity of 28.36% and a net margin of 27.55%. The business had revenue of $12.73 billion for the quarter, compared to analyst estimates of $13.36 billion. During the same period in the prior year, the company earned $2.04 earnings per share. The company’s revenue was down 54.1% on a year-over-year basis. As a group, equities research analysts forecast that Pfizer Inc. will post 3.33 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 5th. Investors of record on Friday, July 28th were issued a dividend of $0.41 per share. The ex-dividend date was Thursday, July 27th. This represents a $1.64 annualized dividend and a dividend yield of 4.80%. Pfizer’s dividend payout ratio (DPR) is presently 43.62%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on PFE shares. HSBC started coverage on shares of Pfizer in a research note on Friday, July 14th. They set a “buy” rating and a $50.00 price objective on the stock. JPMorgan Chase & Co. cut their price target on Pfizer from $45.00 to $41.00 and set a “neutral” rating on the stock in a report on Monday, July 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $75.00 price objective on shares of Pfizer in a research report on Tuesday, September 5th. Truist Financial reduced their target price on shares of Pfizer from $64.00 to $62.00 and set a “buy” rating for the company in a report on Wednesday, August 2nd. Finally, Jefferies Financial Group lowered their price target on shares of Pfizer from $40.00 to $38.00 in a report on Wednesday, August 2nd. Twelve analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $46.35.

Check Out Our Latest Stock Analysis on PFE

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Sunbelt Securities Inc. Acquires 7,015 Shares of Pfizer Inc. (NYSE:PFE)

Pfizer Price Performance

Pfizer Dividend Announcement

Analyst Upgrades and Downgrades

Pfizer Company Profile

Recommended Stories

You might be interested in: